Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.
Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.